These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25467740)

  • 1. A case report of dexmedetomidine used to treat intractable pain and delirium in a tertiary palliative care unit.
    Hilliard N; Brown S; Mitchinson S
    Palliat Med; 2015 Mar; 29(3):278-81. PubMed ID: 25467740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Three successful cases of continuous dexmedetomidine infusion for the treatment of intractable delirium associated with cancer pain].
    Komasawa N; Kimura Y; Hato A; Ikegaki J
    Masui; 2013 Dec; 62(12):1450-2. PubMed ID: 24498781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexmedetomidine use for patients in palliative care with intractable pain and delirium: A retrospective study.
    Yu SY; Schellenberg J; Alleyne A
    PLoS One; 2023; 18(9):e0292016. PubMed ID: 37756303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexmedetomidine as an Option for Opioid Refractory Pain in the Hospice Setting.
    Mupamombe CT; Luczkiewicz D; Kerr C
    J Palliat Med; 2019 Nov; 22(11):1478-1481. PubMed ID: 31194614
    [No Abstract]   [Full Text] [Related]  

  • 5. Dexmedetomidine: exploring its potential role and dosing guideline for its use in intractable pain in the palliative care setting.
    Coyne PJ; Wozencraft CP; Roberts SB; Bobb B; Smith TJ
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):384-6. PubMed ID: 21133747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexmedetomidine Continuous Infusion for Refractory Cancer Pain at End of Life: A Case Report.
    Byrne JM; Mesarwi P; Edmonds KP; Atayee RS
    J Pain Palliat Care Pharmacother; 2022 Sep; 36(3):200-206. PubMed ID: 35913091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexmedetomidine: A Novel Strategy for Patients with Intractable Pain, Opioid-Induced Hyperalgesia, or Delirium at the End of Life.
    Hofherr ML; Abrahm JL; Rickerson E
    J Palliat Med; 2020 Nov; 23(11):1515-1517. PubMed ID: 31944877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexmedetomidine for hyperactive delirium at the end of life: An open-label single arm pilot study with dose escalation in adult patients admitted to an inpatient palliative care unit.
    Thomas B; Lo WA; Nangati Z; Barclay G
    Palliat Med; 2021 Apr; 35(4):729-737. PubMed ID: 33593115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.
    Tsui BC; Davies D; Desai S; Malherbe S
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):678-80. PubMed ID: 15454842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: dexmedetomidine: does it have potential in palliative medicine?
    Prommer E
    Am J Hosp Palliat Care; 2011 Jun; 28(4):276-83. PubMed ID: 21131636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain.
    Amin P; Roeland E; Atayee R
    J Pain Palliat Care Pharmacother; 2014 Sep; 28(3):233-42. PubMed ID: 25102039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Dexmedetomidine Use and Safety Profile in Palliative Care: A Case Report.
    Dieudonné Rahm N; Kemicha T; Papasokrati L; Pautex S
    J Palliat Med; 2023 Jun; 26(6):882-886. PubMed ID: 36603112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine subcutaneous continuous infusion for non-cancer neuropathic pain at home: a case report.
    Julião M; Ulrich J; Calaveiras P; Costa E; Lucas I; Faria de Sousa P
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e902-e907. PubMed ID: 37433626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexmedetomidine: a magic bullet on its way into palliative care-a narrative review and practice recommendations.
    Gaertner J; Fusi-Schmidhauser T
    Ann Palliat Med; 2022 Apr; 11(4):1491-1504. PubMed ID: 35400162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Dexmedetomidine in Pediatric Palliative Care: A Preliminary Study.
    Burns J; Jackson K; Sheehy KA; Finkel JC; Quezado ZM
    J Palliat Med; 2017 Jul; 20(7):779-783. PubMed ID: 28186850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexmedetomidine as an adjuvant analgesic for intractable cancer pain.
    Roberts SB; Wozencraft CP; Coyne PJ; Smith TJ
    J Palliat Med; 2011 Mar; 14(3):371-3. PubMed ID: 21241196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexmedetomidine: a new option for intractable distress in the dying.
    Soares LG; Naylor C; Martins MA; Peixoto G
    J Pain Symptom Manage; 2002 Jul; 24(1):6-8. PubMed ID: 12183087
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor.
    Klepstad P; Borchgrevink P; Hval B; Flaat S; Kaasa S
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):616-9. PubMed ID: 11902308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center.
    Prado BL; Gomes DBD; Usón Júnior PLS; Taranto P; França MS; Eiger D; Mariano RC; Hui D; Del Giglio A
    BMC Palliat Care; 2018 Jan; 17(1):13. PubMed ID: 29301574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain, fentanyl consumption, and delirium in adolescents after scoliosis surgery: dexmedetomidine vs midazolam.
    Aydogan MS; Korkmaz MF; Ozgül U; Erdogan MA; Yucel A; Karaman A; Togal T; Durmus M; Colak C
    Paediatr Anaesth; 2013 May; 23(5):446-52. PubMed ID: 23448434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.